|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||48.44 - 48.90|
|52-week range||45.97 - 64.29|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||26.12|
|Forward dividend & yield||0.85 (1.77%)|
|Ex-dividend date||06 Mar 2023|
|1y target est||59.90|
AXTA vs. NVZMY: Which Stock Is the Better Value Option?
After the first quarter of 2023, Novozymes delivers stronger results than expected with 5% organic sales growth. The company confirms the 2023 outlook of 4-7% which is expected to be driven by pricing and volume growth. COPENHAGEN, Denmark – April 26, 2023. In the first three months of the 2023 financial year, Novozymes delivers 5% organic sales growth, an EBIT-margin of 26.0% before special items, and ROIC including goodwill of 17.7% before special items. A solid start to the year and a strong
PPG vs. NVZMY: Which Stock Is the Better Value Option?
The proposed combination of Novozymes and Chr. Hansen has now been approved by each company’s respective shareholders, and with strong support from the shareholders the two biosolutions companies are now one step closer to uniting. The new company is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large. COPENHAGEN, Denmark – March 30, 2023. Today, Novozymes and Chr. Hansen held their respective extraordinary gener
To the shareholders of NovozymesThe Board of Directors is pleased to invite you to an extraordinary shareholders’ meeting of Novozymes to be held on Thursday March 30, 2023 at 12:00 (noon) CEST at Ballerup Super Arena. Please read the invitation in PDF Til Novozymes’ aktionærerBestyrelsen har hermed fornøjelsen af at invitere til ekstraordinær generalforsamling i Novozymes torsdag den 30. marts 2023 kl. 12.00 i Ballerup Super Arena. Læs venligst den fulde invitation i PDF format Attachments Noti
WLKP vs. NVZMY: Which Stock Is the Better Value Option?
To the shareholders of Novozymes A/S The Board of Directors is pleased to invite you to the company's annual shareholders' meeting on Thursday March 2, 2023 at 4:00 pm CET at Ballerup Super Arena Please read the invitation in PDF Til Novozymes A/S' aktionærer Betyrelsen har hermed fornøjelsen af at invitere dig til selskabets ordinære generalforsamling torsdag den 2. marts 2023 kl. 16.00 i Ballerup Super Arena Læs venligst den fulde invitation i PDF format Attachments Invitation to Novozymes' An
Novozymes is delivering strong growth and earnings in a volatile market environment with 9% organic sales growth in 2022. This marks the highest organic sales growth in more than a decade, and Novozymes is confident about the 2023 outlook of 4-7%. COPENHAGEN, Denmark – January 26, 2026. In the 2022 financial year, Novozymes delivers 9% organic sales growth – 11% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 26.4%, and ROIC including goodwill before
Today, Novozymes and Chr. Hansen have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. The combination is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large. COPENHAGEN, Denmark – December 12, 2022. The proposed combination of Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") will create a strong biosolutions group wi
Novozymes has renewed its climate targets and by 2030 will reduce its absolute CO2 emissions across its operation by 75% and reduce its absolute CO2 emissions from its supply chain by 35%. By 2050, Novozymes will reach net-zero. COPENHAGEN, Denmark – November 10, 2022. Novozymes’ first science-based targets were approved in 2019. Today Novozymes has new, SBTi approved near and long-term science-based emission reduction targets and is one of the first companies in the world to have committed to S
COPENHAGEN, Denmark – November 10, 2022. Novozymes, the world leader in biological solutions, and LinusBio (Linus Biotechnology Inc.), a leader in precision exposome sequencing, today announced the companies are forming a collaboration to test a new, non-invasive technology in a clinical trial. The project will apply LinusBio’s environmental biodynamics platform, enabling detailed temporal mapping of harmful compound exposure, to a clinical trial of probiotics sponsored by Novozymes’ human healt
Novozymes delivered 9% organic sales growth in the first nine months of 2022 and 6% organic sales growth in the third quarter. As announced on October 7, the full-year organic sales growth outlook was raised from 6-8 % to now 8-9 % following a strong performance in the first nine months of the year, and expectedly, continued strong Q4 momentum. COPENHAGEN, Denmark – November 3, 2022. In the first nine months of the 2022 financial year, Novozymes delivers 9% organic sales growth, an EBIT-margin o
Novozymes Named EPA Safer Choice Partner of the Year for Second Consecutive Year World’s Leading Biotech Powerhouse Recognized for Providing and Advocating for Ingredients that Create Safer Detergents Franklinton, NC – November 1, 2022. Novozymes was named a 2022 Safer Choice® Partner of the Year by the U.S. Environmental Protection Agency (EPA) for outstanding achievement in the manufacture of ingredients that are safer for families, pets, workplaces, communities, and the environment. Novozymes
Partners identify new ways to scale Biotalys’ first biofungicide more cost-efficientlyGhent, BELGIUM and Copenhagen, DENMARK , Oct. 24, 2022 (GLOBE NEWSWIRE) -- Biotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company protecting crops and food with protein-based biocontrol solutions, and Novozymes, a world leader in biotech solutions including Ag biologicals, today announced the successful outcome of the feasibility study for Evoca™*, Biotalys’ first proprietary biocontrol product
Novozymes delivered solid earnings and double-digit organic sales growth in both the first half and in the second quarter. Despite the volatile market environment, the company narrows its full-year organic sales outlook upwards from 4-8% to now 6-8% and raises EBIT-margin expectations from 25-26% to now 26-27%. COPENHAGEN, Denmark – August 11, 2022. Novozymes delivers 10% organic sales growth and an EBIT-margin of 26% in the first half of the year, with 18% organic sales growth in DKK. Good mome
Novozymes has experienced unprecedented cost-inflation on raw materials, energy, and logistics. To recover these headwinds, substantial price increases will be implemented. COPENHAGEN, Denmark – 15 July 2022. Novozymes has been able to partially shield its customers from a large part of the global challenges, securing business continuity and high price stability relative to other suppliers. However, Novozymes will further substantially increase prices at a level at least in line with the current
AXTA vs. NVZMY: Which Stock Is the Better Value Option?
A question on the minds of many investors right now is how economic uncertainty will continue to affect large cap companies, such as Novozymes A/S (CPH:NZYM B)...
ESI vs. NVZMY: Which Stock Is the Better Value Option?
AdobeStock_436255963 Biopolishing for MMCF is not just a quality win in terms of pilling performance. It also delivers excellent drapability as well as a soft hand feel. GettyImages-899207120 More consumers are conscious about how clothes are made and how they impact the environment. Non-polished vs biopolished fabric Top image: Not biopolished. Bottom image: Biopolished. Consumer and regulatory demands for more sustainable clothing and textiles are growing and the fashion industry is rising to